UK Medical Cannabis Registry: Assessment of clinical outcomes in patients with insomnia
Abstract Introduction The primary aim of this study was to assess changes in sleep‐specific health‐related quality of life (HRQoL) for those prescribed cannabis‐based medicinal products (CBMPs) for insomnia. Methods A case series of UK patients with insomnia was analyzed. Primary outcomes were chang...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-02-01
|
| Series: | Brain and Behavior |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/brb3.3410 |
| _version_ | 1797293112147574784 |
|---|---|
| author | Kavyesh Vivek Zekiye Karagozlu Simon Erridge Carl Holvey Ross Coomber James J. Rucker Mark W. Weatherall Mikael H Sodergren |
| author_facet | Kavyesh Vivek Zekiye Karagozlu Simon Erridge Carl Holvey Ross Coomber James J. Rucker Mark W. Weatherall Mikael H Sodergren |
| author_sort | Kavyesh Vivek |
| collection | DOAJ |
| description | Abstract Introduction The primary aim of this study was to assess changes in sleep‐specific health‐related quality of life (HRQoL) for those prescribed cannabis‐based medicinal products (CBMPs) for insomnia. Methods A case series of UK patients with insomnia was analyzed. Primary outcomes were changes in the Single‐Item Sleep‐Quality Scale (SQS), Generalized Anxiety Disorder‐7 (GAD‐7), and EQ‐5D‐5L at up to 6 months from baseline. Statistical significance was identified as a p value < .050. Results 61 patients were included in the analysis. There was an improvement in the SQS from baseline at 1, 3, and 6 months (p < .001). There were also improvements in the EQ‐5D‐5L Index value and GAD‐7 at 1, 3, and 6 months (p < .050). There were 28 (45.9%) adverse events recorded by 8 patients (13.1%). There were no life‐threatening/disabling adverse events. Conclusion Patients with insomnia experienced an improvement in sleep quality following the initiation of CBMPs in this medium‐term analysis. Fewer than 15% of participants reported one or more adverse events. However, due to the limitations of the study design, further investigation is required before definitive conclusions can be drawn on the efficacy of CBMPs in treating insomnia. |
| first_indexed | 2024-03-07T20:08:10Z |
| format | Article |
| id | doaj.art-a3e581e5239f4578802925ef8044de7a |
| institution | Directory Open Access Journal |
| issn | 2162-3279 |
| language | English |
| last_indexed | 2024-03-07T20:08:10Z |
| publishDate | 2024-02-01 |
| publisher | Wiley |
| record_format | Article |
| series | Brain and Behavior |
| spelling | doaj.art-a3e581e5239f4578802925ef8044de7a2024-02-28T03:46:31ZengWileyBrain and Behavior2162-32792024-02-01142n/an/a10.1002/brb3.3410UK Medical Cannabis Registry: Assessment of clinical outcomes in patients with insomniaKavyesh Vivek0Zekiye Karagozlu1Simon Erridge2Carl Holvey3Ross Coomber4James J. Rucker5Mark W. Weatherall6Mikael H Sodergren7Imperial College Medical Cannabis Research Group, Department of Surgery and CancerImperial College LondonLondonUKImperial College Medical Cannabis Research Group, Department of Surgery and CancerImperial College LondonLondonUKImperial College Medical Cannabis Research Group, Department of Surgery and CancerImperial College LondonLondonUKDepartment of MedicineCuraleaf ClinicLondon UKDepartment of MedicineCuraleaf ClinicLondon UKDepartment of MedicineCuraleaf ClinicLondon UKDepartment of MedicineCuraleaf ClinicLondon UKImperial College Medical Cannabis Research Group, Department of Surgery and CancerImperial College LondonLondonUKAbstract Introduction The primary aim of this study was to assess changes in sleep‐specific health‐related quality of life (HRQoL) for those prescribed cannabis‐based medicinal products (CBMPs) for insomnia. Methods A case series of UK patients with insomnia was analyzed. Primary outcomes were changes in the Single‐Item Sleep‐Quality Scale (SQS), Generalized Anxiety Disorder‐7 (GAD‐7), and EQ‐5D‐5L at up to 6 months from baseline. Statistical significance was identified as a p value < .050. Results 61 patients were included in the analysis. There was an improvement in the SQS from baseline at 1, 3, and 6 months (p < .001). There were also improvements in the EQ‐5D‐5L Index value and GAD‐7 at 1, 3, and 6 months (p < .050). There were 28 (45.9%) adverse events recorded by 8 patients (13.1%). There were no life‐threatening/disabling adverse events. Conclusion Patients with insomnia experienced an improvement in sleep quality following the initiation of CBMPs in this medium‐term analysis. Fewer than 15% of participants reported one or more adverse events. However, due to the limitations of the study design, further investigation is required before definitive conclusions can be drawn on the efficacy of CBMPs in treating insomnia.https://doi.org/10.1002/brb3.3410benzodiazepinescannabis‐based medicinal productsinsomniasleep quality |
| spellingShingle | Kavyesh Vivek Zekiye Karagozlu Simon Erridge Carl Holvey Ross Coomber James J. Rucker Mark W. Weatherall Mikael H Sodergren UK Medical Cannabis Registry: Assessment of clinical outcomes in patients with insomnia Brain and Behavior benzodiazepines cannabis‐based medicinal products insomnia sleep quality |
| title | UK Medical Cannabis Registry: Assessment of clinical outcomes in patients with insomnia |
| title_full | UK Medical Cannabis Registry: Assessment of clinical outcomes in patients with insomnia |
| title_fullStr | UK Medical Cannabis Registry: Assessment of clinical outcomes in patients with insomnia |
| title_full_unstemmed | UK Medical Cannabis Registry: Assessment of clinical outcomes in patients with insomnia |
| title_short | UK Medical Cannabis Registry: Assessment of clinical outcomes in patients with insomnia |
| title_sort | uk medical cannabis registry assessment of clinical outcomes in patients with insomnia |
| topic | benzodiazepines cannabis‐based medicinal products insomnia sleep quality |
| url | https://doi.org/10.1002/brb3.3410 |
| work_keys_str_mv | AT kavyeshvivek ukmedicalcannabisregistryassessmentofclinicaloutcomesinpatientswithinsomnia AT zekiyekaragozlu ukmedicalcannabisregistryassessmentofclinicaloutcomesinpatientswithinsomnia AT simonerridge ukmedicalcannabisregistryassessmentofclinicaloutcomesinpatientswithinsomnia AT carlholvey ukmedicalcannabisregistryassessmentofclinicaloutcomesinpatientswithinsomnia AT rosscoomber ukmedicalcannabisregistryassessmentofclinicaloutcomesinpatientswithinsomnia AT jamesjrucker ukmedicalcannabisregistryassessmentofclinicaloutcomesinpatientswithinsomnia AT markwweatherall ukmedicalcannabisregistryassessmentofclinicaloutcomesinpatientswithinsomnia AT mikaelhsodergren ukmedicalcannabisregistryassessmentofclinicaloutcomesinpatientswithinsomnia |